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Abstract: The zebrafish (Danio rerio) is a small vertebrate ideally suited to the modeling of human
diseases. Large numbers of genetic alterations have now been modeled and could be used to study
organ development by means of a genetic approach. To date, limited attention has been paid to the
possible use of the zebrafish toolbox in studying humanmitochondrial disorders a↵ecting the nervous
system. Here, we review the pertinent scientific literature discussing the use of zebrafish in modeling
gene mutations involved in mitochondria-related neurological human diseases. A critical analysis
of the literature suggests that the zebrafish not only lends itself to exploration of the pathological
consequences of mitochondrial energy output on the nervous system but could also serve as an
attractive platform for future drugs in an as yet untreatable category of human disorders.
Keywords: zebrafish; mitochondria; nervous system development; neurodegenerative conditions
1. Introduction
The term mitochondrial disease is classically used in reference to defects of the oxidative
phosphorylation (OxPhos) system and defects of energy metabolism. Instead, the term mitochondrial
medicine serves to group together, in a single category, the ample array of clinical presentations
associated with these defects, which range from single organ failure to complex phenotypes, including
neurodegenerative diseases and cancers [1]. The human mitochondrial proteome is believed to be
made up of over 1500 proteins (Human MitoCarta (www.broadinstitute.org)) [2]. This reflects the
intrinsic complexity of the organelle and makes it conceivable that dysfunctions of mitochondria
give rise to highly heterogeneous clinical presentations. Patients may be a↵ected at any age and
with multisystem involvement, that often a↵ects organs with high energy demands. However, how
defects in mitochondria can cause such widespread range of human disorders remains to be unveiled.
Mitochondria are dynamic andmobile organelles that play an essential role in several cellular processes,
Int. J. Mol. Sci. 2019, 20, 2409; doi:10.3390/ijms20102409 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 2409 2 of 24
such as the generation and regulation of cellular energy, initiation of apoptosis, iron-sulfur cluster
biogenesis, and calcium bu↵ering [3,4]. The OxPhos is the process by which mitochondria produce the
adenosine triphosphate (ATP) molecules needed by the cells. This system consists of five multimeric
enzyme complexes (EC): Complex I (EC 1.6.5.3) or NADH:ubiquinone reductase, CI; Complex II (EC
1.3.5.1) or succinate dehydrogenase, CII; Complex III (EC 1.10.2.2) or quinol-cytochrome c (cyt c)
reductase, CIII; Complex IV (EC 1.9.31) or cyt c oxidase (COX), CIV; Complex V (EC 3.6.14) or
FoF1-ATPase, CV; and two electron transport carriers, namely, ubiquinone (coenzyme Q, CoQ) and
cyt c [5]. The OxPhos is under a dual genetic control: thirteen of the key structural polypeptides that
constitute the multimeric subunits of the respiratory chain complexes and ATP synthase are encoded
by the mitochondrial DNA (mtDNA), in addition to two ribosomal RNAs (rRNAs) and 22 transfer
RNAs (tRNAs), which are required to perform autochthonous protein synthesis [6]. Conversely,
approximately eighty of the remaining proteins making up the OxPhos complexes are encoded by
nuclear DNA (nDNA) genes. Although it encodes the basic machinery for protein synthesis, as well as
replication, repair, and transcription, human mtDNA remains entirely dependent upon the nucleus for
the provision of enzymes and accessory components. Hence, a genetic classification of OxPhos-related
mitochondrial diseases distinguishes two broad categories: disorders due to mutations in the mtDNA,
and obeying to the rules of mitochondrial genetics, and disorders due to mutations in the nDNA, which
are governed by canonic Mendelian genetics [1]. Correct communication between the two genomes is
crucial for mtDNA integrity, copy number regulation and mitochondrial protein production. Thus,
not only nucleotide variants in the mtDNA itself, but also mutations in nuclear genes involved in
mtDNA replication and maintenance might disrupt the integrity of the mitochondrial genome and
influence its functional properties [7]. The pathological consequences impact mostly on tissues highly
dependent upon ATP production such as heart, muscle, and particularly the central (CNS) and the
peripheral nervous systems (PNS) [8].
Producing up to 90% of ATP molecules generated in the brain, the OxPhos is responsible for
powering cell signaling and neuronal activity processes. It is not too surprising that mitochondria
also play a key role in aging-related neurodegenerative disorders such as Parkinson’s disease (PD),
Alzheimer’s disease, Huntington’s disease, and in amyotrophic lateral sclerosis [9,10]. Among the
identified genes found to be associated with inherited forms of neurodegenerative disorders, at least
half directly or secondarily a↵ect one or several mitochondrial functions [11]. In cells, mitochondria
actively fuse and divide (fission), branch, and change their size in a dynamic manner. This process,
named mitochondrial network dynamics, seems indispensable to guarantee an appropriate population
of healthy and functional mitochondria at every time [12]. Mitochondria network dynamics work in
tight collaboration with the mitophagy pathway to ensure the quality control of these organelles [13].
Mitophagy is a selective formofmacro-autophagy that degrades damaged or unnecessarymitochondria.
Defects in this process have been reported as crucial at the onset and progression of neurodegenerative
diseases where autophagic failure is one of the main factors contributing to neuronal cell death [14].
Neurons are particularly vulnerable to autophagic impairment as well as to mitochondrial dysfunction
because of their high energy demands and to their post-mitotic non-proliferating nature [15]. Altogether,
these considerations lead to the idea that mitochondria, as well as being a focus for a considerable
amount of research, provide important clues to be potential target for therapies in a broad range of
neurodegenerative diseases.
2. Zebrafish Resources to Mimic Human Diseases
The discovery of a large number of mitochondrial genes causing human diseases prompted the
generation of a number of animal models, including simple invertebrate (Saccharomyces cerevisiae,
Caenorhabditis elegans and Drosophila melanogaster) and more sophisticated mammalian models (such
asMus musculus), which replicate various aspects of neurological disorders caused by mitochondrial
damage, and thus are considered useful to understand the pathophysiological mechanisms and to
evaluate putative therapeutic candidates [16,17]. Nevertheless, there remains a need to achieve more
e cient high-throughput screenings of vertebrate models in order to fully address the questions of
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mitochondrial physiology and function to study the e↵ects of mitochondrial damage in individual
organs and in the animal behaviors. Recently, the zebrafish has emerged as an excellent organism for
studying a broad range of human genetic diseases, including those a↵ecting the di↵erent functional
structures of the CNS [18,19]. In this view, the zebrafish is attractive for several reasons including its
particular biology and genetics. The zebrafish breed with high rates and big numbers of fertilized
eggs, which are transparent, tiny, and mobile during the key developmental stages, can be easily
obtained daily. The healthy zebrafish embryos develop rapidly and in synchrony, within one day of
development, many key features of the CNS are detectable and can be studied up to the larval stage
and beyond. Another major advantage of using zebrafish is the simplicity and e↵ectiveness with which
genes can be manipulated to allow biological observations in the cells of the developing embryos.
Other advantages are the availability of zebrafish genome data [20] and the accessibility of over 80%
of its gene structures in several publicly available databases (Ensembl (www.ensembl.org), Entrez
(www.ncbi.nlm.nih.gov/gquery), UCSC Genome Browser (https://genome.ucsc.edu/), and ZFIN, the
Zebrafish Model Organism Database (zfin.org)). Zebrafish genes show a high degree of synteny across
vertebrate species as well as 50–80% homology with most human sequences. Comparison with the
human reference genome sequences shows that approximately 70% of human genes have at least one
obvious zebrafish ortholog [21]. In addition, molecular pathways are phylogenetically well conserved,
and the basic physiology is similar to that of mammals [22]. Orthologs for most human genes can be
easily identified by bioinformatics tools and manipulated to mimic human pathologies by gain- and
loss-of-function approaches. However, it has to be noticed that zebrafish gene identification can be
complicated by the fact that several genes are duplicated as a result of a whole genome duplication
event that occurred during teleost fish evolution; this implies that in zebrafish specific functions could
be partitioned between the two duplicated genes, or simply lost or disrupted for one of the genes,
or even complemented if one of the two copies is disrupted [23]; nevertheless, in some cases duplication
events enhance the possibility to obtain information on gain/loss of some gene functions.
A standard technique for studying embryo development is to knockdown a specific gene function
by injecting gene-specific phosphorodiamidate morpholino oligonucleotides (MOs) in early embryonic
stages [24]. MOs are chemically modified antisense oligonucleotides that can specifically bind
messenger RNAs (mRNAs) and transiently block translation (when they are targeted to sequences near
the initiation codon) or splicing (when they are targeted to exon-intron boundaries), thus providing
gene knockdown in the zebrafish embryo. However, major limitations of this technique are the
transient e↵ects of MOs and the multiple o↵-target e↵ects which fail to impact on the juvenile or adult
phenotype [25]. More recently, the successful application of new technologies for genome editing, such
as zinc finger nucleases [26,27], transcription activator-like e↵ectors (TALENs) [28], and technologies
based on clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated
protein 9 (Cas9) (CRISPR-Cas9) systems [29], has allowed more profitable targeted mutagenesis and
functional gene ablation in zebrafish. Another approach is the undirected mutation-driven method
using irradiation, retroviruses or the most commonly used chemical mutagens such as the DNA
alkylating agent N-ethyl-N-nitrosourea (ENU) [30]. In the last years, the reverse genetics approaches,
where DNA mutations can be studied without an observable phenotype, have been further improved
by recent advances in genomic technologies and next-generation sequencing (NGS) [30,31]. The results
of this progress have led to an increase in the number of novel zebrafish mutated lines.
3. Zebrafish Resources to Explore Mitochondrial Physiology
In the last decade, zebrafish modeling has been used to study various aspects of mitochondrial
physiology, e.g., the dynamics of the cellular mitochondrial network, the mitochondrial life cycle, and
mtDNA metabolism during development. The technologies applied to study these aspects in the
zebrafish model have rapidly increased as shown in Table 1 and briefly described below.
Through a balance between fusion and fission, mitochondria maintain a web-shaped network
in cells [32,33]. The study of mitochondrial morphology in the zebrafish was initially conducted
using molecular probes [34] or immunofluorescent antibodies [35]. In order to study changes
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in mitochondrial morphology at the organism level in normal or disease conditions in real time,
transgenic zebrafish model expressing mitochondrially-targeted fluorescent proteins (green/red) were
created [36,37]. Several neurodegenerative diseases have been linked with deficits in mitochondrial
axonal transport [38]. To study the “life cycle” of mitochondria and their dynamics in neurons,
transgenic lines were generated using Gal4/UAS genetics that allows the expression of transgene
labeled mitochondria [39] also in specific neural cells. By using this tool, studies on mitochondrial
transport related to neurological disease were conducted in Rohon-Beard sensory neurons [40,41],
retinal ganglion cells [42], motor neurons [43], and dopaminergic neurons [44] of zebrafish, developing
di↵erent transgenic lines with fluorescently labeled mitochondria.
Recently, Mandal and colleagues (2018) have optimized a direct visualization of mitochondria
and the analysis of their lifetime, health, and function in axons of the posterior lateral line (pLL) in
zebrafish, using a panel of technologies that allows investigating in vivo several mitochondrial aspects
in the zebrafish model (Table 1) [45].
Song and colleagues (2009) have investigated on mitochondrial reactive oxygen species (ROS)
formation using the oxidative fluorescent dye dihydrorodamine-123 (DHR-123) [46], while the
examination of mitochondrially derived ROS was conducted in zebrafish using a live cell redox sensor
that identifies mitochondria-generated superoxides (MitoSOXTM) [47]. Biothilos, such as cysteine
(Cys) and homocysteine (Hcy) have an important role in ROS homeostasis in mitochondria and
are very sensitive to the oxidative stress [48]. The real-time monitoring of Cys and Hcy levels in
zebrafish mitochondria allows monitoring their oxidative stress level. For this purpose, Yue et al.
(2018) developed a ratiometric two-photon fluorescent probe (Mito-MQ) for measuring Cys/Hcy level
in mitochondria and applied this technology in vivo, into 5-day-old zebrafish larvae [48]. All these
studies provide a starting point for performing further mitochondrial studies under physiological or
disease conditions in this relatively simple organism [49]. Micro-oxygraphy has been used in the whole
organism, especially at the early stages of embryo development, to study bioenergetic metabolism
and mitochondrial physiology related to neurodegenerative conditions [50]. Embryos have also been
shown to lend themselves to the evaluation of the total number of mtDNA genomes at di↵erent
developmental stages and to the assessment of the spatial expression of genes regulating mtDNA
biogenesis and OxPhos complexes [51].
Due to the fact that manymitochondrial defects a↵ect the nervous system, andmany structure and
function of the zebrafish CNS are very similar to the human ones [52], we recapitulated the scientific
literature concerning the use of zebrafish for modelling neurological disorders caused bymitochondrial
alterations. A critical review of what has been done to date might be of use for future investigations.
Table 1. Tools used for the investigation of mitochondrial physiology.
Tools Investigation Refs
MitoTracker Deep Red and MitoTracker Green FM Mitochondrial activity in skin [34]
mitochondrial localization
sequence- enhanced GFP embryos Mitochondrial morphology in real time [53]
Mito:mCherry KBP/KIAA1279 function [37]
Oxidative fluorescent dye dihydrorodamine-123
(DHR-123) Mitochondrial ROS formation [46]
Seahorse XF24 Extracellular Flux Analyzer Mitochondrial bioenergetics [50]
Relative quantification by RT-PCR and
immuno-probes
Genes involved in mtDNA replication and
transcription and genes of the OxPhos system [51]
MitoSOXTM Examination of mitochondria-derived ROS [47]
MitoFish, Tg(elavl3.2:Gal4-VP16)mde4/
Tg(UAS-E1b:mYFP,mitoCFP)mde
Time-lapse imaging of mitochondrial transport in
Rohon-Beard sensory neurons [41]
MitoDsRed transgenic line: reporter
UAS–mitoDsRed–polyA crossed to
isl1(ss):Gal4VP16:14XUAS-GFP fish.
Morphology and motility of mitochondria in
somatosensory neurons [40]
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Table 1. Cont.
Tools Investigation Refs
MitoGFP In vivo study of mitochondria in retinal ganglion cellof kif5Aamutant [42]
Tg(hb9:MTS-Kaede) Mitochondrial dynamics in motor neurons inCMT2A mutants [43]
Tg(otpb:Gal4); Tg(UAS:mtPAGFP:mtDsRed2) Measurement of mitochondrial transport indopaminergic neurons [44]
Anti-mitochondrial membrane 20 (TOM20)
and anti-mitochondrial
aspartate aminotransferase (mAAT)antibodies
Study of ES1, a mitochondria-enlarging factor in
cones [35]
5kbneurod:mito-TagRFP plasmid Role for Actr10 in dynactin-mitochondria interaction [36]
Tg(5kbneurod:mitomEos)y586
Mitochondrial lifetime and the timeline of
mitochondrial turnover and temporal dynamics of
mitochondrial gain and loss from axon terminals
[45]
5kbneurod:mito-Timer ROS production, an indicator of mitochondrial health [45]
Vital dye TMRE Measurement of potential/pH across themitochondrial inner membrane [45]
G-GECO1; Tg(5kbneurod:GGECO)nl19; R-GECO1;
Tg(5kbneurod:mito-R-GECO)nl20 Mitochondrial calcium bu↵ering in neurons [45]
ATP:ADP dual ratiometric sensor PercevalHR Productivity of mitochondria in the cell body andaxon terminal of pLL sensory axons [45]
Mito-MQ Oxidative stress by Real-time monitoring Cys andHcy levels [48]
4. Modeling Mitochondrial Defects in Zebrafish
Mutations in mtDNA or nDNA genes that encode mitochondrial proteins cause a heterogeneous
group of disorders primarily due to dysfunctions of the OxPhos and electron transport chain. However,
other mutations that involve mitochondrial physiology, such as ion channels, quality control system,
mitochondrial carriers, or cellular perturbations that a↵ects mitochondria, such as mitochondrial
transport cause an energy deficiency that a↵ects high demand tissues including nervous system.
In this review, we summarized the current use of the zebrafish as a relatively simple and e cient
tool for studying the e↵ects of gene mutations involved in mitochondria-related human neurological
diseases (Figure 1).
Mutated genes modeled in zebrafish are presented in the following sections, covering six main
topics; the list of genes investigated is summarized in Table 2.
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Figure 1. Summary of mitochondria-related genes involved in neurological human disorders, 
modeled in mutant zebrafish. Mutations in genes involved in mitochondrial electron transport 
chain, physiology, quality control, dynamics and metabolism, as well as mutations in selected genes 
encoding carriers and ion channels, can disrupt the integrity of the mitochondrion and/or influence 
its functions, thus determining the onset of neurological disorders. 
Mutated genes modeled in zebrafish are presented in the following sections, covering six main 
topics; the list of genes investigated is summarized in Table 2. 
Figure 1. Sum ary of mitochondria-related genes involved in neurological human disorders, modeled
in mutant zebrafish. Mutations in genes involved in mitochondrial electron transport chain, physiology,
quality control, dynamics and metabolism, as well as mutations in selected genes encoding carriers
and ion channels, can disrupt the integrity of the mitochondrion and/or influence its functions, thus
determining the onset of neurological disorders.
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Table 2. Human genes related to mitochondrial disorders a↵ecting the nervous system modeled in zebrafish.
Gene Function Modeling Zebrafish Phenotype Refs
Defects of functioning and assembly of OxPhos complex
NDUFAF7 Assembly factor of Complex I MO-mediated knockdown Delayed hatching times and morphological abnormality [54]
COXVa Structural component of COX MO-mediated knockdown Developmental defects in endodermal tissue, cardiac function andswimming behavior [55]
SURF1 Assembly factor of COX MO-mediated knockdown Developmental defects in endodermal tissue, cardiac function andswimming behavior [55]
COA6 Cu-delivery pathway for COX assembly MO-mediated knockdown Heart developmental defects [56]
ETFDH Electron transfer flavoprotein dehydrogenase xaviermutant zebrafish line
Altered energy metabolism, dysregulated ROS production, increased
aerobic glycolysis, motility defects, abnormal glial patterning,
reduced motor axon branching and neuromuscular synapse number
[46]
MO-mediated knockdown Bent tail and reduced heartbeat, aberrant swimming behavior, andreduced neuromuscular synaptogenesis [46]
ETFA
Receiving of electrons from dehydrogenases
involved in fatty acid  -oxidation, amino acid and
choline metabolism
dark xavier (dxavu463)mutant
zebrafish line
Increased number of neural progenitor cells and accumulation of
neutral lipid and cerebroside sulphate in brain, hepatic steatosis and
dysmorphic kidneys, and hypomyelination
[57]
Ion channels and mitochondrial defects
SCN1A Brain-specific voltage-activated sodium channel scn1Labmutant zebrafish line Increased behavioral seizure activity and increased glycolytic rate [58]
Defects of mitochondrial quality control system
PARK2 E3 ubiquitin ligase MO-mediated knockdown High susceptibility to the MPP
+, Dopaminergic loss neurons and
complex I deficiency [59]
Overexpression of parkin in
transgenic zebrafish cell lines Protective reaction against cell death induced by proteotoxic stress [60]
PINK1 Mitochondrial serine/threonine kinase MO-mediated knockdown High sensitivity to MPTP, increase of ROS level, activation ofapoptotic signaling [61]
pink1 null mutant zebrafish line PD-phenotype and altered biogenesis of mitochondria [62]
PARL
Presenilin-associated rhomboid-like protein that is
part of the PINK1 and Parkin pathway. In
zebrafish are present two paralogs (parla and parlb)
MO-mediated knockdown High rate of mortality in early larvae, mis-patterned dopaminergicneurons in morphants [63]
PARK7
Pleiotropic function: transcriptional regulator,
antioxidant scavenger, redox sensor and roles as a
chaperone with protease activity
MO-mediated knockdown Neurons are highly sensitive to hydrogen peroxidase [64]
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Table 2. Cont.
Gene Function Modeling Zebrafish Phenotype Refs
Transgenic line
Tg(gfap:egfp-2A-flag-zDJ-1)
Astrocytic dj-1 overexpression protects mutants from neurological
damage induced by the PD-related neurotoxin MPP+ [65]
LRRK2 Cytosolic protein MO-mediated knockdown Neurodegeneration and locomotion defects [66]
SNCA
Soluble protein primarily expressed in the neural
tissue. In zebrafish are present only two synuclein
isoforms,   and  2-synuclein
Overexpression of human
↵-synuclein
Changes in mitochondrial density and morphology, mitochondrial
fragmentation, reduced mitochondrial motility and ensuing synaptic
dysfunction and degeneration
[67]
Double MO-mediated
knockdown Motor impairments and reduction of dopamine level [68]
Defects of mitochondrial dynamics
MFN2 Promotion of mitochondria movement and fusion MO-mediated knockdown
Reduction of the survival rate, motor impairment or
unresponsiveness to touch. Generalized impairment in the axonal
structure of primary motor neurons. Presence of shortened or
missing axons, altered distribution of acetylcholine receptors. Altered
alignment of the myofibers
[69]
mfn2L285X mutant zebrafish line
Altered swimming and progressive loss of motor function.
Alterations at the neuromuscular junction. Altered mitochondrial
dynamics and change in mitochondrial morphology
[70]
Overexpression ofMFN2
carrying the c.281G>A (R94Q)
and c.227T>C (L76P) mutations
in transgenic zebrafish cell lines
Reduction of mitochondria transport along the axon in p.R94Q
expressing larvae. Reduction of density of moving mitochondria in
the case of p.L76P overexpression.
[43]
OPA1 Fusion of the outer and inner mitochondrialmembranes MO-mediated knockdown
Developmental delay, decreasing of the blood circulation velocity,
and reduction of the eye size and the heart rate. Reduction of the
startle response and bioenergetics defects
[71]
KBP/KIAA1279 Binding protein of the kinesin motor proteinsKIF1B and KIF1C kbpst
23 mutants
Delay in development of peripheral axons. Axons degeneration.
Reduction in myelination. Disorganization of the axonal cytoskeleton.
Reduction in the number of axonal mitochondria.
[37]
MO-mediated knockdown Axonal defects in peripheral and central nervous systems [37]
KIF5A Transport processes kif5Aamutant zebrafish line Hyperexcitability, peripheral polyneuropathy, and axonaldegeneration [38]
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Table 2. Cont.
Gene Function Modeling Zebrafish Phenotype Refs
Mitochondrial carrier deficiency
SLC25A1 Mitochondrial solute carrier family MO-mediated knockdown
Altered tail morphology, impaired swimming and touch-evoked
escape responses. Abnormal neuromuscular junction development.
Short and erratic outgrowth toward the muscle fiber of the motor
axon terminals with no complete synapse formation. Hindbrain,
heart, yolk sac, and tail edema. Abnormal heart development with
reduced blood flow to the tail (in severe phenotypes)
[72]
SLC25A46 Mitochondrial solute carrier family MO-mediated knockdown
Curly-tail morphology and altered swimming. Shorter axon tracts in
motor neurons and fewer neuronal processes in spinal cord.
Degenerate neurons with incomplete mitochondrial fission,
mitochondria aggregated and misplaced.
[73]
MO-mediated knockdown Poor motility and the loss of spinal motor neurons. [74]
Metabolic mitochondrial disorders
OPA3 Inner mitochondrial membrane protein MO-mediated Knockdown Increased 3-methylglutaconic acid (MGC), and features mimickingmovement disorders [75]
PDHC Nuclear-encoded mitochondrial matrixmultienzyme complex
Spontaneous zebrafish mutant
(noa strain, carrying a mutation
in the pdh-e2 subunit)
Retinal abnormalities, defects of synaptic transmission and of light
adaptation in cone photoreceptor cells, premature death, lethargy,
expanded melanophores, and absence of feeding behavior
[76]
TSEN54 Subunit of the tRNA-splicing endonuclease(TSEN) complex
MO-mediated Knockdown,
mutagenesis strategy
Brain hypoplasia and loss of structural integrity, increased cell death,
and early lethality in zebrafish [77]
RARS2 Mitochondrial arginyl-tRNA synthetase gene MO-mediated knockdown Brain hypoplasia, cell death and neurodegeneration [77]
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4.1. Defects of Functioning and Assembly of the OxPhos Complex
The term “primary mitochondrial diseases” refers to a wide range of complex syndromes
collectively characterized by impaired OxPhos function with clinical expression especially in the
brain, muscle, and eyes [78,79]. The deficiency of OxPhos complex assembly factors causes several
severe neurological disorders in human such as cardiomyoencephalopathy, leukoencephalopathy,
psychomotor delay, seizures, and Leigh syndrome [5]. Currently, very few studies have been conducted
on specific gene mutations to investigate these disorders using zebrafish models. Complex I is the
largest enzyme of the mitochondrial OxPhos system and its deficiency caused by pathogenic mutations
in genes encoding the structural subunits have been identified and associated with mitochondrial
disorders [80].
A mutation on the methyltransferase NADH:Ubiquinone Oxidoreductase Complex Assembly
Factor 7 (NDUFAF7), which is an assembly factor of complex I, has been found in association with
the reduction of intracellular ROS and ATP levels and with the reduction of Complex I activity, and
it has also been correlated with pathologic myopia [81]. Zurita Rendon and colleagues investigated
the function of NDUFAF7 in models in vivo: Ndufaf7 knockout mice and MO knockdown zebrafish.
Delayed hatching times and morphological abnormality resulted by the disruption of the NDUFAF7
paralogue gene, and the steady-state levels of complex I was specifically a↵ected by theMO knockdown
in zebrafish [54]. Furthermore, mutations of COX complex have been described in a number of human
mitochondrial diseases with peripheral neuropathies. Among the mitochondrial diseases, COX
deficiency can present with a number of di↵erent infantile clinical phenotypes including classical Leigh
syndrome, fatal infantile COX deficiency, and hypertrophic cardiomyopathy and myopathy [82]. Most
COX deficiencies in humans are related to defective function of structural or ancillary proteins making
up the holocomplex, including the assembly genes SCO2 and SURF1. Zebrafish morphants of the
orthologs of either human COXVa or SURF1 showed a profound histochemical defect of COX activity
and impaired holoenzyme assembly [59]. As a consequence, morphants showed a dramatic increase
in apoptosis in hindbrain and neural tube and exhibited a severe motility defect. By contrast, the
heart of mutant zebrafish lacked apoptotic cells but showed increasingly poor performance over time,
a phenotype consistent with tissue energy deficiency [55]. More recently, copper supplementation has
been shown to rectify the disassembly pattern of the COX holocomplex in a zebrafish line where the
COX assembly factor 6 (COA6) was knocked-down [56].
Multiple acyl-CoA dehydrogenase deficiency (MADD) is an autosomal recessive disorder, which
is clinically heterogeneous; patients with this disease display multiple defects including neurological
impairment. This condition is due to deficiency of any one of three proteins: the alpha (ETFA)
and beta (ETFB) subunits of mitochondrial electron transfer flavoprotein, or the electron transfer
flavoprotein dehydrogenase (ETFDH). The clinical pictures due to the di↵erent enzyme defects
appear to be indistinguishable; each defect can lead to a range of mild or severe cases, depending
presumably on the location and nature of the intragenic lesion [83]. Inactivation of the etfdh gene (xavier
zebrafish mutant) resulted in severe metabolic abnormalities. In particular, there were biochemical
abnormalities consistent with mitochondrial dysfunction, and increased neuronal proliferation caused
by the activation of the PPARG-ERK pathway [46]. A new mutant strain termed dark Xavier, because of
its enlarged, dark and fatty liver [57], was generated. This mutant strain, carrying mutations in etfa,
displayed severe neurologic deficits including encephalopathy that is usually seen in patients with
MADD, and recapitulated many key clinical and metabolic features seen in MADD patients such as
multi-organ defects of the brain, liver and kidney.
4.2. Ion Channels and Mitochondrial Defects
Dravet syndrome (DS), a severe genetic form of epilepsy, has been associated with mutations
in the sodium channel protein type 1 subunit alpha (SCN1A) [58]. Starting from the observation
of mitochondrial defects in muscle biopsies in DS patients, OxPhos and mitochondrial glycolysis
were studied in the scn1Lab zebrafish mutant, a zebrafish model of DS. Even though no defects of
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OxPhos complexes I–IV were observed in scn1Labmutants, the authors noted a decreased expression
of glycolysis related genes [58]. A decrease of complex I activity was suspected to be induced by the
oxidative stress and post-translational oxidative modification caused by the spontaneous seizures,
observed in these mutants [58].
4.3. Defects of Mitochondrial Quality Control System
The underlying causes of several neurological disorders converge on impaired mitochondrial
physiology and maintenance. PD is a frequent neurological disorder caused by dopaminergic neuronal
death in the substantia nigra, resulting in a reduced level of dopamine in the striatum that is the direct
cause of motor dysfunction of PD patients [84]. PD-associated neuronal loss is strictly connected
with localized mitochondrial dysfunction and oxidative stress before the clinical onset of motor
symptoms [85]. Among gene products associated with hereditary PD we find those located within
(PARKIN, PINK1, PARL, and DJ-1) or linked to (LRRK2) mitochondria. PARKIN and PINK1 are
neuroprotective proteins which act together in a mitochondrial quality control pathway promoting the
clearance of damaged mitochondria via autophagy [86].
PARKIN is an E3 ubiquitin ligase and like the human protein, zebrafish parkin is ubiquitously
expressed throughout embryonic development and in adult tissues. PARKIN is involved in oxidative
stress and the stable overexpression of parkin is able to protect fish against proteotoxic stress preventing
cell death [67]. In zebrafish, loss of parkin elicits an approximately 20% loss of dopaminergic neurons
in the ventral diencephalon. Morphants do not show any abnormal mitochondrial morphology, but
mitochondrial complex I activity is spectrophotometrically reduced [59].
PINK1 is a ubiquitously expressed protein with an N-terminal mitochondrial-targeting motif
and a conserved serine⁄threonine kinase domain, and two of its targets have been identified: TNF
receptor-associated protein 1, which protects against oxidative stress [87], and DRP1, which promotes
mitochondrial fission [88]. PINK1 seems to act similarly to PARKIN in oxidative stress conditions
in particular, protecting neurons against stress-induced mitochondrial damage and apoptosis [89].
Zebrafish pink1 is expressed ubiquitously in the brain, and its abrogation results in a selective decline
of some important mRNAs, and only distinct groups of dopaminergic neurons are sensitive to
loss of pink1 in zebrafish [61]. The pink1 null mutant zebrafish line, referred to as pink / , shows
mitochondrial dysfunction and loss of dopaminergic neurons [62]. Di↵erential transcriptomic
investigations in pink1 morphants [90] revealed global impairment of TGF-  signaling, retinoic
acid receptor (RAR) activation, altered biogenesis of mitochondria, and, among the major hits,
dysfunction of the hypoxia-induced signaling pathway when compared with a wild-type strain.
Soman and co-workers have highlighted that the pharmacological and/or genetic inhibition of the
inner mitochondrial membrane calcium uniporter is able to rescue loss of dopaminergic neurons in
pink /  mutants recovering the PD-phenotype [91]. Recently, this transgenic line (pink / ) has been also
exploited to develop new class of stress-dependent autophagy-stimulating drugs to prevent the loss of
dopaminergic neurons in PD-zebrafish model [92].
PARL codes for an integral membrane protease of the inner mitochondrial membrane having
a role in the normal tra cking and processing of PINK1 and PARKIN within mitochondria [93].
Moreover, PARL cleaves the optic atrophy 1 protein (OPA1) [94] that is a crucial protein involved
in the fusion of inner mitochondrial membranes and in the formation of cristae, crucial for proper
mitochondrial metabolism in early development [71]. Bioinformatics analyses revealed that in zebrafish
there are two paralogues, parla and parlb, whose transcripts are both ubiquitously expressed during
embryogenesis [63]. The PD-phenotype caused by the KD of both parl genes can be rescued by the
overexpression of human PARLmRNA. Morphants showed that cell death likely occurred because parl
is unable to prevent mitochondrial fission or to produce soluble OPA1, which prevents the widening of
the cristae junction and inhibits the release of cyt c from the mitochondria [63].
PARK7 encodes DJ-1 that is localized in the mitochondrial matrix; the zebrafish orthologue of
DJ-1 is expressed in adult brain, muscle and gut, and is predicted to have high sequence homology of
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83% with human DJ-1 protein [95]. Loss of human DJ-1 leads to an altered mitochondrial morphology
contributing to the increased cellular sensitivity to oxidative stress [96]. In zebrafish, knockdown
of dj-1 does not cause decrease in number of dopaminergic neurons but leads to high susceptibility
to programmed cell death activated by p53 [64]. Moreover, it is well known that the astrocytes,
which outnumber neurons in the brain, have a key role in neuronal protection controlling redox
homeostasis [84] producing neuron-protective factors [85]. The selective astroglial dj-1 overexpression
in transgenic zebrafish line Tg(gfap: egfp-2A-flag-zDJ-1) is able to protect fishes from neurological
damage probably through the up-regulation of redox and inflammatory proteins regulated by Nrf2
activation [65].
LRRK2 has mainly cytoplasmic localization but associates also with the outer mitochondrial
membrane. LRRK2 interacts with Parkin in cultured mammalian neuronal cells [97], and with PRDX3,
an important antioxidant scavenger of hydrogen peroxide within mitochondria [98]. In human
neuronal cell lines, the overexpression of LRRK2 causes mitochondrial fragmentation associated with
increased levels of DLP1, a mitochondrial fission protein [99]. Knockdown of lrrk2 in morphants
zebrafish causes neurodegeneration and locomotion defects that can be rescued both by expressing
the wild-type LRRK2 and with the administration of L-dopa, a drug commonly used for treating PD
patients [66].
Another zebrafishmodel for PD has been created by overexpression of human ↵-synuclein (SNCA)
in zebrafish peripheral sensory neurons that leads to amoderate cell death, whereas many axons exhibit
di↵use or focal swellings [67]. Under basal conditions SNCA does not interact with mitochondrial
membranes; nonetheless, ultrastructural studies reveal that a fraction of synuclein normally associates
to mitochondria, and it can produce mitochondrial fragmentation and functionality impairment of
the complex I activity [100]. The orthologue of human ↵-synuclein appears not to be present in the
zebrafish genome [101]. However, the two synuclein isoforms,   and  2-synuclein, can compensate
the absence of ↵-synuclein, and their loss induces motor impairments and reduction of dopamine
levels [68].
All of these observations lend further support to the notion that mitochondrial dysfunction plays
a key role in zebrafish models of PD and that zebrafish represents a proficient model to investigate
in vivo the alterations of mitochondrial physiology underlying neurological disorders.
4.4. Defects of Mitochondrial Dynamics
Mitochondrial dynamics, such as fission, fusion and transport, are fundamental processes for
neurons because pre- and post-synaptic terminals need high amount of energy and Ca2+ bu↵ering
and are particularly susceptible to the deficiency of these systems [102]. When mtDNA and proteins
accumulate defects, damaged mitochondria need to be replaced by newly ones assembled in the body
of the cell and then transported along the axons. This anterograde and retrograde movement along the
microtubules within neurons, vital to maintain energy homeostasis and essential neuronal activities, is
mediated by motor/adaptor proteins and cytoskeletal elements [43,102]. Fission is necessary for the
transport and to regulate mito-apoptosis of damaged mitochondria, while fusion allows the survival of
damaged or senescent mitochondria by exchanging materials among mitochondria themselves [103].
Mutations in theMFN2 (mitofusin 2) and OPA1 genes, both involved in mitochondrial transport
and/or fusion, cause two hereditary neurodegenerative disorders, respectively an axonal peripheral
neuropathy (Charcot-Marie-Tooth Type 2, CMT2) and the dominant optic atrophy (DOA) [73]. MFN2
codes for a dynamin-like GTPases located in the outer mitochondrial membrane, and its major
function is promoting mitochondria movement and fusion. Vettori and colleagues (2011) developed a
zebrafish model for the neuromuscular disorder CMT2 [69]. Patients with CMT2A are characterized
by muscular atrophy, distal muscle weakness accompanied by distal sensory loss, foot deformities and
gait impairment. Zebrafish knockdown of mfn2 showed not dramatic alterations of the mitochondrial
network structure but significant motor impairment or unresponsiveness to touch. Additional
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accompanied by the presence of shortened or missing axons, altered distribution of acetylcholine
receptorswith a reduction of the number and size of their clusters, which are important in neuromuscular
junctions for the synaptic signals from the motor axon. Moreover, mfn2 morphants displayed also
an altered alignment of the myofibers [69]. Additionally, a spontaneous mutant strain harboring
a nonsense mutation in mitofusin 2 (mfn2L285X) presented altered mitochondrial dynamics and a
change of mitochondrial morphology [70]. The phenotype of this mutant strain revealed also a
progressive motor dysfunction and alterations at the neuromuscular junction, associated with defective
axonal transport of mitochondria, resembling the progressive motor dysfunction observed in CMT2
patients [70]. In order to study p.L76P and p.R94Q, two missense mutations inMFN2, mutant capped
MFN2mRNAs were injected in the one-cell stage embryos of the new-created zebrafish line Tg(hb9:
MTS-Kaede), characterized by the fluorescent labeling of motor neuron mitochondria [43]. Mutant
cappedMFN2mRNAs produced a significant reduction in the density of movingmitochondria for both
mutations, but a significant reduction of mitochondrial density was observed in p.L76P overexpression
in zebrafish motoneurons [43]. On the contrary, a reduction of the transport of mitochondria along the
axon was observed in p.R94Q expressing larvae, suggesting a di↵erent mechanism of action of the two
MFN2mutations [43].
KIF5A (Kinesin Family Member 5A) is another gene involved in mitochondrial transport, and
mutations of this gene have also been associated with CMT2 [38]. KIF5A belongs to the Kinesin
superfamily proteins (KIFs), which are microtubule-based molecular motors. Mammals possess three
KIF5s: Kif5B that is ubiquitously expressed, and KIF5A and KIF5C that are neuron-specific [104].
In zebrafish there are five kif5 genes (kif5Aa, kif5Ab, kif5Ba, kif5Bb, and kif5C) and kif5Aa, kif5Ab, and
kif5C are the most expressed in neural tissues [104]. Campbell and colleagues observed that only the
kif5Aamutated zebrafish line showed larval lethality and sensorimotor deficits similar to CMTs [38].
Kinesin proteins have an important role during neuronal development, but additional factors
a↵ect their regulation [37]. Kif1-binding protein (KBP/KIAA1279) binds to the motor domain of the
KIF1B and KIF1C, and homozygous mutations of KBP cause Goldberg–Shprintzen syndrome, a severe
disorder characterized by neurological symptoms, mental retardation, and disruption of white matter
tracts. Lyons and colleagues (2008) investigated the KPB paralogue gene in zebrafish kbpst23 mutants
and demonstrated its key role in the regulation of axonal cytoskeleton organization, regulation of
axonal outgrowth speed, localization of axonal cargo and maintaining of axonal longer-term integrity.
The consequence on mitochondria of the KBP mutation in zebrafish was a mislocalization and a
reduction in the number of axonal mitochondria [37].
OPA1, a dynamin-related GTPase, is involved in the fusion of the outer and inner mitochondrial
membranes, andgenemutations are associatedwith the autosomal dominant optic atrophy (ADOA) [71].
ADOA is characterized by progressive loss of visual acuity, desensitization of central visual field, optic
nerve pallor, and eventual blindness [71]. In zebrafish, the opa1morphants morphologically showed a
reduction of the eyes size. In morphant 72 hpf (hours-post-fertilization) embryos a reduction of the
startle response and of the locomotor activity were also observed associated to bioenergetics defects [71].
Furthermore, morphants showed upregulation of pgc1a, the orthologue of the master regulator of
mitochondrial biogenesis, at 24 and 48 hpf, suggesting increasedmitochondrial biogenesis [71]. The opa1
morphants allowed elucidating the connection between opa1 depletion, mitochondrial dysfunction,
and development [71].
These results implicate that modeling in zebrafish proteins regulating mitochondrial dynamics
might serve to study the distribution of mitochondria in early stages of development and to improve
knowledge on the role of mitochondrial networks in neurodegeneration.
4.5. Mitochondrial Carrier Deficiency
Mitochondrial carriers (MCS) are transport proteins that allow small molecules to shuttle between
mitochondria and cytoplasm playing a central role in mitochondrial function to regulating cellular
metabolism [105] (and literature cited therein). Few studies have addressed the role of mitochondrial
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carriers in neurological disorders and no less the functions of many human carriers still remain better
to be characterized. In mammals, MCS comprise the transporters of the 53-member canonical SLC25
family and a lesser number of identified non-canonical transporters.
SLC25A1, the first member of the solute carrier family SLC25, is the mitochondrial citrate carrier
that mediates the exchange of mitochondrial citrate/isocitrate with cytosolic malate [106,107]. SLC25A1
is involved in fatty acid and sterol biosynthesis, gluconeogenesis and glycolysis [106], maintenance of
chromosome integrity and regulation of autophagy [108,109]. The identification of patients harboring
mutations in SLC25A1 and presenting congenital myasthenic syndrome 23 (CMS23) [72] or the more
severe combined D-2- and L-2-hydroxyglutaric aciduria (D2L2AD) [110,111] phenotype confirms the
relevance of this protein in humans. SLC25A1 dysfunction interferes with brain, eye, and possibly
neuromuscular development, in addition to causing a distinctive urinary organic acid profile. Notably,
knocking down the two zebrafish SLC25A1 orthologues (i.e., slc25a1a and slc25a1b) by injection of
antisense MOs in fertilized eggs mirrors human CMS23 in terms of variable brain, eye, and cardiac
involvement, and leads to abnormalities in the neuromuscular junction, regardless of the severity of
the phenotype [72]. MO-injected embryos display altered tail morphology, and impaired swimming
and touch-evoked escape responses at 48 hpf. Histologically, muscle morphology is normal but
neuromuscular junction development is abnormal. Motor axon terminals show short and erratic
outgrowth toward the muscle fiber with no evidence of complete synapse formation, suggesting
presynaptic nerve terminal abnormalities. Knockdown embryos often show edema of the hindbrain,
heart, yolk sac and tail. Abnormal heart development is observed with increased severity of phenotype
with reduced blood flow to the tail [72].
SLC25A46, another member of the mitochondrial solute carrier family SLC25, was found to
correspond to UGO1, a mitochondrial fusion factor in Saccharomyces cerevisiae. Previously, genome
studies had linked SLC25A46 to atopic dermatitis but a high expression of the SLC25A46 transcript had
been observed in the spinal cord, cerebellum, and optic chiasm neurons of patients [73]. Severe slc25a46
zebrafish morphants showed a curly-tail morphology while wild-appearing larvae display an altered
swimming [73] associated to significantly shorter axon tracts in motor neurons and fewer neuronal
processes in spinal cord neuropil of larvae. The dendritic degeneration observed in slc25a46morphants
was consistent with CMT2 pathology. In degenerating neurons, an incomplete mitochondrial fission
was observed, and mitochondria resulted aggregated and predominantly in the apical portion of the
soma [73]. Interestingly, di↵erent mutations in SLC25A46, that cause loss of function of the mutant
protein, were also found in patients with the pontocerebellar hypoplasia (PCH) [74]. SCL25A46 seems
to act as a pro-fission component regulating mitochondrial dynamics in humans and zebrafish.
4.6. Metabolic Mitochondrial Disorders
Metabolic disorders causing neurological impairment have successfully beenmodelled in zebrafish.
To date, these disorders include Coste↵ syndrome, Barth syndrome, pyruvate dehydrogenase complex
(PDHC) deficiency, and PCH.
Coste↵ syndrome is a neuro-ophthalmological disorder characterized by increased urinary
excretion of 3-methylglutaconic acid and 3-methylglutaric acid, early-onset optic atrophy, and later
occurrence of spasticity and extra-pyramidal features [112]. Coste↵ syndrome is caused by mutations
in OPA3 that encodes an inner mitochondrial membrane protein. In zebrafish opa3mRNA is expressed
in the optic nerve and retinal layers, brain, inner ear, heart, liver, intestine, and swim bladder.
Morphants do not show vision loss, hyperreflexia or spasticity characteristic of the human disorder
but a penetrant behavior resembling the ataxia and extrapyramidal (bradykinesia) features seen in
Coste↵ syndrome [75].
The PDHC is a nuclear-encoded mitochondrial matrix multienzyme complex that catalyzes the
irreversible conversion of pyruvate into the acetyl form of coenzyme A (acetyl-CoA), thus playing a
central role in linking glycolysis to the tricarboxylic acid cycle and lipogenic pathways [113]. Deficient
biochemical activity causes fatal neonatal conditions including congenital lactic acidosis, growth
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retardation and Leigh syndrome. A spontaneous zebrafish mutant of PDHC deficiency, exhibits
phenotypes similar to human patients and the administration of a ketogenic diet resembling the leading
therapy proposed for children with PDHC deficiency is able to recover the normal condition [76].
Currently, PCH classification comprises 11 types based on distinct genetic causes and clinical
features. Thedisease is associatedwithprenatal onset, hypoplasia/atrophyof the cerebellum, hypoplasia
of the ventral pons, progressive microcephaly and variable neocortical atrophy [114]. Zebrafish models
of PCH have been generated through the knockdown of tsen54 and rars2, two genes encoding proteins
associated with tRNA splicing and tRNA aminoacylation. Studies in morphants suggest a common
disease pathway may exist between TSEN54- and RARS2-related PCH, which may involve a tRNA
processing-related mechanism [77].
All these studies reveal that the zebrafishmodeling is sensitive tometabolic insults from embryonic
stages, and thus it may be useful in order to understand disease mechanisms and critical to develop
therapeutic options in inborn errors of metabolism a↵ecting mitochondrial functions [22].
5. Zebrafish as In Vivo Model to Test New Compounds in Mitochondrial Related Neurological
Disorders
The zebrafish represents a valuable model for investigating the molecular mechanisms underlying
the neurotoxicity of agents a↵ecting the normal neuronal mitochondrial physiology and for testing
potential neuroprotective compounds. As mentioned above, defects in mitochondrial biogenesis,
mitochondrial dynamics, and mitochondrial respiratory chain activities lead to a several human
diseases; below, we provide several new models for mitochondrial dysfunction which could have great
potential for diagnostics and therapies in neuronal mitochondrial-related diseases.
The impairment of the OxPhos system a↵ects directly mitochondrial function causing several
disease phenotypes. The inhibition of ATP production can be induced in zebrafish by exposure to 2-4
dinitrophenol (DNP), a weight loss agent with significant toxicity, used in research as an uncoupler of
OxPhos [115]. Past mid-embryogenesis embryos treated by DNP show a strong decrease in ATP levels
and developmental defects. The neural tissues emerge particularly a↵ected by DNP, which inhibits
motor neuron axon arbor outgrowth and proper formation of the retina [116].
COX, the terminal oxidase enzyme of the mitochondrial respiratory chain, needs copper (Cu)
as an essential micronutrient required for its assembly and activity. Mutations in genes related to
the delivery for Cu to COX leads to a respiratory deficiency and fatal mitochondrial disease. In a
zebrafish model of Cu deficiency, low nanomolar quantity of the anticancer drug elesclomol (ES) is
able to recover phenotypes associated with Cu deficiency by increasing cellular and mitochondrial Cu
content [117].
Pyruvate oxidation defects are also among the causes of mitochondrial diseases mainly due to
deficiency of subunits of PDHC. In zebrafish, noamutants (carrying a mutation in the pdh-e2 subunit)
treated with 4-phenylbutyrate (PBA), a histone deacetylase inhibitor usually employed in urea cycle
disorders, showed a significant decrease in melanophore expansion, more active locomotion, and
lower levels of lactate and pyruvate than untreated mutants. These findings prompted evaluation
of PBA in human mutant cells and in a mouse model of PDHC deficiency [118]. Another zebrafish
mutant (noir strain, harboring a stop codon mutation in the pdh subunit E1   gene) showed a retinal
phenotype and reduced locomotion and fatigue, and the phenotype improved upon treatment with a
ketogenic diet causing an increase in acetyl-CoA production, able to bypass the metabolic block [119].
Recently, the idebenone metabolite 6-(9-carboxynonyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone
(QS10) was used to recover of respiration and to allow zebrafish wild-type embryos survival after the
treatment with the neurotoxin Rotenone, an inhibitor of complex I [120]. Currently, idebenone was
proposed as a first-line therapy in Leber’s hereditary optic neuropathy (LHON) syndrome because its
capacity to improve visual defects in a subset of patients [121,122].
It was widely described [123] that also in zebrafish some structural analogs of dopamine, such as
6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), selectively
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a↵ect dopaminergic neurons inducing a PD-like phenotype. In particular, the metabolite of MPTP,
1-methyl-4-phenylpyridinium (MPP+), inhibits complex I and impairs mitochondrial respiration [124].
These findings allowed generating numerous zebrafish PD-models to test new potential compounds
with neuroprotective activity.
The transgenic zebrafish line Tg(ETvmat2: GFP) showed a significant neurodegeneration of
dopaminergic neurons and locomotor dysfunction upon treatment with MPTP [125]. This model has
widely been used as an in vivo tool for screening neuroprotective agents for PD, such as Paenolum, that
is the main component derived from the bark of the Paeonia su↵ruticosa, acting as a strong antioxidant
and reducing the mitochondrial cell death pathway [126].
Moreover, it has been shown that the exposure of 24 hpf zebrafish embryos with melatonin
added together with MPTP or added once MPTP removal, prevents and recovers the parkinsonian
phenotype restoring mitochondrial normalcy and the brain function in zebrafish. Melatonin is able to
restore in a dose-specific manner the gene expression and the normal function of the PD-related genes
park2/pink1/park7 loop, and also the normal motor activity of the embryos [127]. Furthermore, sleep
disorders constitute major nonmotor features of PD and several trials indicate that melatonin and its
analogs are useful in treating disturbed sleep in PD patients [128,129].
Zhang and co-workers (2017) developed a multifactorial zebrafish drug-screening platform
discovering a series of piperazine phenothiazines, with neuroprotective activity that rescued
stress-induced mitochondrial dysfunction thus preventing dopaminergic neuron loss in a zebrafish
model of pink1 deficiency [92]. In particular, trifluoperazine (TFP) is able to increase autophagic flux
acting downstream of, or parallel to, pink1/parkin to restore TFEB translocation, which is a master
regulator of the autophagy-lysosomal pathway [92].
Another zebrafish model of PD was generated by treating the fish with 6-OHDA, and the
marine-derived compound 11-dehydrosinulariolide (11-de) increases cytosolic or mitochondrial dj-1
expression, and then activates the downstream Akt/PI3K, p-CREB, and Nrf2/HO-1 pathways [130].
Several marine-derived natural compounds have been approved for clinical use [131]. Huang and
co-workers summarized those e↵ective for the treatment of PD and that have been approved in
clinical trials [132]. All these evidences suggest that zebrafish can be a powerful instrument for a full
understanding of mitochondrial pathogenesis related to the nervous system.
6. Materials and Methods
A literature search was performed on original articles published by the 28th November 2018,
which were identified from PubMed using the terms <<zebrafish>> AND <<neurological dysfunction
[All Fields] >> and <<zebrafish [All Fields]>>AND <<mitochondrion [All Fields]>>as queries. These
searches yielded respectively 80 and 503 matches in PubMed. We also performed an active search of
the references listed in publications discussing neurological diseases associated with mitochondrial
damage and the use of zebrafish. Altogether, we critically re-evaluated 571 articles net of repetitions
but 526 were excluded because they did not present direct research on zebrafish, mitochondria and
neurological disorders. Overall, 47 articles were included in the review.
7. Conclusions
Mitochondria are dynamic organelles that carry out many cell functions and, in particular, they
are known as the “powerhouse” of the cell, generating ATP via OxPhos. The high number/density
of mitochondria within neurons to attend their high energy demands provides a rationale for the
sensitivity of the CNS to energy deficits due to mitochondrial impairment.
The large number of novel genotypes and the increased number of mutants developed in the last
years, as well as the new tools developed for analyzing mitochondrial lifetime, health, and function in
zebrafish combined with the use of MO and CRISPR-Cas9 systems, have allowed to investigate and
understand the role of several genes involved in human mitochondrial-related neurological disorders.
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The list of identified mutations associated with mitochondrial alterations in neurological disorders
is still growing thanks to the use of NGS in the diagnostics of neurological human diseases. Zebrafish
has proven itself to be an applicable and versatile model to investigate mutations responsible of
mitochondrial disorders.
In parallel, one of the key characteristics of the zebrafish is that it can serve as a platform in
high-throughput screenings performed to assess drug e cacy or to analyze o↵-target e↵ects in a
whole-organism context. Many drugs for treating human diseases have comparable e↵ects in zebrafish
embryos, and it is likely that additional compounds identified by large-molecule screening in zebrafish
will be worth testing in mammalian systems. The zebrafish can be exploited as a practical tool for
performing more detailed and rapid studies to shed light on the e↵ects and consequences (inert,
ameliorating, or detrimental) during development, which have rarely been analyzed in proper clinical
trials. In addition, the model can serve while assessing safety and e cacy of drugs in their early stages
of development.
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Abbreviations
6-OHDA 6-hydroxydopamine
acetyl-CoA Acetyl form of coenzyme A
ADOA Autosomal dominant optic atrophy
Cas9 CRISPR-associated protein 9
CMT2 Charcot-Marie-Tooth Type 2
CNS Central nervous system
COA COX assembly factor
CoQ Coenzyme Q
COX Cytochrome c oxidase
CRISPR Clustered regularly interspaced short palindromic repeats
Cys Cysteine
cyt c cytochrome c
DNP 2-4 dinitrophenol
DOA Dominant optic atrophy
DS Dravet syndrome
EC Enzyme complexes
ENU N-ethyl-N-nitrosourea
Hcy Homocysteine
MADD Multiple acyl-CoA dehydrogenase deficiency
MCS Mitochondrial carriers
MO Morpholino oligonucleotide
MPP+ 1-methyl-4-phenylpyridinium
MPTP 1-methylmethyl-4-phenylphenyl-1,2,3,6-tetrahydropyridinetetrahydropyridine
mRNA Messenger RNA
mtDNA Mitochondrial DNA
nDNA Nuclear DNA
NGS Next-generation sequencing
OxPhos Oxidative phosphorylation
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PBA 4-phenylbutyrate
PCH Pontocerebellar hypoplasia
PD Parkinson’s disease
PDHC Pyruvate dehydrogenase complex
pLL Posterior lateral line
PNS Peripheral nervous system
ROS Reactive oxygen species
rRNA Ribosomal RNA
TALEN Transcription activator-like e↵ector
tRNA Transfer RNA
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